Invalidation of Antibody Genus Claims Highlights Need for Comprehensive Patent Strategies
In a significant development within the field of Intellectual Property, the US Court of Appeals for the Federal Circuit has invalidated another series of antibody genus claims. The case was described as being “materially indistinguishable” from those in the 2023 Supreme Court of the United States case, Amgen v. Sanofi. The Federal Circuit concluded that…